Business Wire
Welcome
  • Log In
  • Sign Up
Search News:
Help
http://www.gilead.com
February 25, 2013 04:30 PM Eastern Daylight Time 

Gilead Sciences to Present at Two Upcoming Investor Conferences

- 2013 Citi Global Healthcare Conference on February 26th -
- 2013 RBC Capital Markets’ Healthcare Conference on February 27th -
- Webcasts Available Through Gilead Corporate Website -

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company will be webcasting its corporate presentation at two upcoming investor conferences: the Citi Global Healthcare Conference and the RBC Capital Markets’ Healthcare Conference, both taking place in New York.

Robin Washington, Gilead’s Senior Vice President and Chief Financial Officer, will provide an overview of the company at the Citi conference on Tuesday, February 26 at 11:05 a.m. Eastern Time (ET) and the RBC conference on Wednesday, February 27 at 10:30 a.m. ET.

To access the live webcasts or replays via the Internet log on to www.gilead.com. Please connect to the company’s website at least 15 minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. The replay will be available for 14 days following the presentation.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

Contacts

Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investor Relations)

Recent Stories

  • View Press Release
    La Agencia Europea del Medicamento aprueba la solicitud de comercialización de sofosbuvir de Gilead para el tratamiento de la hepatitis C
    May 22, 2013
    Translations Available
    FOSTER CITY, California--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) ha anunciado que la solicitud de autorización de comercialización (MAA en sus siglas en inglés) de la empresa para sof... more »
  • View Press Release
    Europäische Arzneimittelbehörde bestätigt Gileads Vermarktungsantrag für Sofosbuvir zur Behandlung von Hepatitis C
    May 22, 2013
    Translations Available
    FOSTER CITY, Kalifornien (USA)--(BUSINESS WIRE)--Das Unternehmen Gilead Sciences, Inc. (NASDAQ: GILD) hat heute bekannt gegeben, dass die Marketing Authorisation Application (MAA) des Unternehmens ... more »
  • View Press Release
    L’Agence européenne des médicaments accepte la demande d’autorisation de mise sur le marché de Gilead pour le sofosbuvir comme traitement de l’hépatite C
    May 22, 2013
    Translations Available
    FOSTER CITY, Californie--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq : GILD) a annoncé aujourd’hui que la demande d’autorisation de mise sur le marché (AMM) pour le sofosbuvir, un analogue de nu... more »
More Stories
RSS feed for Gilead Sciences, Inc.
http://www.gilead.com

Release Versions

  • EON: Enhanced Online News

Company Information Center

Gilead Sciences, Inc. RSS feed for Gilead Sciences, Inc.

NASDAQ:GILD

Share

  • Facebook
  • Twitter
  • LinkedIn
  • Delicious
  • Reddit
  • StumbleUpon
  • Digg
  • MySpace
  • Newsvine
  • Google Bookmark
  • Yahoo! Bookmark
  • EmailEmail
Tweet
  • EmailEmail
All News
Business Wire
  • Home
    • Home
    • Membership Benefits
    • Submit a Press Release
  • News
    • All News
    • News with Multimedia
    • News by Industry
    • News by Subject
    • News by Language
    • RSS Feeds
    • Business Wire Mobile
    • Features
    • Company NewsCenters
    • Annual Reports
  • Events
    • Trade Shows & Events
    • Earnings & Conference Calls
    • Business Wire Events
  • PR Services
    • Press Release Distribution
    • Distribution Lists
    • Industry Targeting
    • LatinoWire & Ethnic Media
    • Public Policy Wire
    • Trade Show Services
    • Photos & Multimedia Marketing
    • GloMoSoMe
    • Measurement & Analytics
    • Monitoring
    • Fax & Email Services
    • Online Newsrooms
    • News Feeds
  • IR Services
    • Material News Disclosure
    • XBRL
    • EDGAR (US)
    • IPO Services
    • SEDAR (Canada)
    • European Disclosure
    • Corporate Social Responsibility (CSR)
    • Investor Targeting
    • Mobile Alerts
    • Fax & Email Services
    • IR Sites
    • IR Resource Center
  • SEO Services
    • Press Release Optimization
    • EON: Enhanced Online News
    • Webinars & Resources
  • Journalist Tools
    • PressPass: Your News
    • Conduct Surveys
    • Business Wire News Feeds
    • Business Wire News On Your Website
    • Journalism Associations
  • Support & Education
    • FAQ
    • How to Write a Press Release
    • How To Optimize a Press Release for Search
    • Find Your News Online
    • Sample Press Release
    • Features News Tips
    • International Media Tips
    • SEC Regulations
    • Exchange Guidelines
    • White Papers
    • Webinars & Podcasts
    • Get WiredIn!
  • About Us
    • Business Wire Newsroom
    • Contact Us
    • History
    • Jobs
  • About Us
  • Contact Us
  • Site Map
  • Privacy Statement
  • Terms of Use
  • ©2013 Business Wire

More Business Wire sites

  • Canada
  • UK/Ireland
  • Deutschland
  • France
  • Italy
  • Japan
  • EON: Enhanced Online News
  • Tradeshownews.com
  • PYMNTS.com

About Us

  • Business Wire Newsroom
  • Contact Us
  • Business Wired blog

News on BusinessWire.com

  • All News
  • RSS Feeds
  • Business Wire Mobile Apps

Follow Us on Twitter

  • @BusinessWire
  • @BWSportsWire
  • @BWPolitics
  • @BWCSRNews
  • @EONpr
  • @TradeshowNews
  • @BW_Canada
  • @BWIntlMedia
  • @BWInfoDiva
  • @BusinessWireFR
  • @BWLatinoWire

Like Us on Facebook

  • Business Wire
  • Tradeshow News